ArticleJournal of medicinal chemistry2015
Structure-guided design and optimization of dipeptidyl inhibitors of norovirus 3CL protease. Structure-activity relationships and biochemical, X-ray crystallographic, cell-based, and in vivo studies.
Article in Journal of medicinal chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 53 citations in OpenAlex.
- Discovery of Small Molecules Targeting Norovirus 3CL Protease by Multi-Stage Virtual Screening.International journal of molecular sciences · 2025Article
- Potent small molecule inhibitors against the 3C protease of foot-and-mouth disease virus.Microbiology spectrum · 2024Article
- On the origins of SARS-CoV-2 main protease inhibitors.RSC medicinal chemistry · 2024Review
- Article
- PRSC chemical biology · 2023Review
- Potent Protease Inhibitors of Highly Pathogenic Lagoviruses: Rabbit Hemorrhagic Disease Virus and European Brown Hare Syndrome Virus.Microbiology spectrum · 2022Article
- A Bibliometric Analysis of the Literature on Norovirus Disease from 1991-2021.International journal of environmental research and public health · 2022Article
- Structural similarities between SARS-CoV2 3CLFrontiers in chemistry · 2022Article
- Identification of compelling inhibitors of human norovirus 3CL protease to combat gastroenteritis: A structure-based virtual screening and molecular dynamics study.Frontiers in chemistry · 2022Article
- Norovirus Protease Structure and Antivirals Development.Viruses · 2021Review
- Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 MJournal of molecular biology · 2021Article
- 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.Science translational medicine · 2020Article
- Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against MbioRxiv : the preprint server for biology · 2020Article
- Article
- Putative structural rearrangements associated with the interaction of macrocyclic inhibitors with norovirus 3CL protease.Proteins · 2019Article
- Norovirus antivirals: Where are we now?Medicinal research reviews · 2019Review
- Review
- Protease inhibitors broadly effective against feline, ferret and mink coronaviruses.Antiviral research · 2018Article
- Synthesis and antiviral evaluation of novel peptidomimetics as norovirus protease inhibitors.Bioorganic & medicinal chemistry letters · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
Norovirus infection constitutes the primary cause of acute viral gastroenteritis. There are currently no vaccines or norovirus-specific antiviral therapeutics available for the management of norovirus infection. Norovirus 3C-like protease is essential for viral replication, consequently, inhibition of this enzyme is a fruitful avenue of investigation that may lead to the emergence of antinorovirus therapeutics. We describe herein the optimization of dipeptidyl inhibitors of norovirus 3C-like protease using iterative SAR, X-ray crystallographic, and enzyme and cell-based studies. We also demonstrate herein in vivo efficacy of an inhibitor using the murine model of norovirus infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.